The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | 2025 updates in targeting KRAS and KRAS wild type pancreatic cancer
Benedikt Westphalen, MD, Ludwig Maximilian University (LMU) Hospital Munich, Munich, Germany, highlights recent advancements in the treatment of pancreatic cancer, including the development of drugs targeting the oncogenic KRAS oncogene. Combinational therapies and innovative approaches, such as precision oncology for patients with RAS wild-type pancreatic cancer, are also being assessed in trials. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
These are very exciting times for doctors, caregivers treating patients with pancreatic cancer. Because for the first time in years, in decades ever, we now have drugs that target the oncogenic KRAS oncogene. KRAS mutations are present in more than 90% of all patients with pancreatic cancer. And until a couple of years ago, it was common sense that there would never be a drug targeting KRAS...
These are very exciting times for doctors, caregivers treating patients with pancreatic cancer. Because for the first time in years, in decades ever, we now have drugs that target the oncogenic KRAS oncogene. KRAS mutations are present in more than 90% of all patients with pancreatic cancer. And until a couple of years ago, it was common sense that there would never be a drug targeting KRAS. Now we have approved drugs and we see a lot of novel therapeutic agents entering the arena in the treatment of pancreatic cancer. So this opens up a lot of new possibilities for combinational therapies for neoadjuvant settings and really bringing innovation to a group of patients that has been lacking really innovative approaches over the last couple of years. There’s a small group of patients presenting with RAS wild-type pancreatic cancer. This is a poster child for precision oncology because you find a lot of targetable alterations, BRAF mutations, fusion events and all of these can be targeted upon comprehensive genomic profiling identifying this rare subset often found in younger patients for example And this is the second group that we’re really interested in.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
